U.S. Reference Data

Obesity, diabetes, and GLP-1 statistics.

Key U.S. figures for writers, clinic teams, and researchers. Every statistic includes its source and reporting date.

Last updated October 2, 2026

At A Glance

A clearer picture of care demand.

Weight management sits at the intersection of chronic-disease care, access, and documentation. This page brings together recent public data on obesity, diabetes, and GLP-1 medication use in one stable reference. It is informational only and is not medical advice.

Population Data

Obesity and weight statistics

These figures use national CDC datasets and reporting. Obesity measures in these sources are based on body mass index, which has recognized limitations.

72.4%

of U.S. adults had overweight, including obesity

This is the CDC estimate for adults age 20 and older.

Source: CDC FastStatsAugust 2021-August 2023

25%+

adult obesity prevalence in every reporting state and territory except D.C.

In the CDC’s 2025 maps, the District of Columbia was the sole reporting jurisdiction below 25%, at 24.2%.

Source: CDC, Adult Obesity Prevalence Maps2025 data, updated September 24, 2026

35.5%

adult obesity prevalence in the Midwest

The Midwest had the highest regional prevalence in the CDC’s 2025 reporting, followed by the South at 34.8%.

Source: CDC, Adult Obesity Prevalence Maps2025 data, updated September 24, 2026

42

reporting areas had at least 35% obesity prevalence among adults ages 40-59

This includes 40 states and two territories in the CDC’s 2025 age-specific reporting.

Source: CDC, Adult Obesity Prevalence Maps2025 data, updated September 24, 2026

Care And Access

Diabetes and GLP-1 care statistics

These figures combine current CDC estimates with KFF survey findings on public use and affordability.

18%

of adults said they had ever taken a GLP-1 medication

The KFF survey includes use for weight loss or chronic conditions such as diabetes or heart disease.

Source: KFF Health Tracking PollNovember 2025

12%

of adults said they were currently taking a GLP-1 medication

KFF reported this was up from 6% in its May 2024 survey.

Source: KFF Health Tracking PollNovember 2025

Methodology And Sources

How to use this page.

Each figure is taken directly from the named source and retains that source's reporting period. CDC figures are drawn from national surveillance, survey, and 2025 state-based reporting. GLP-1 use and affordability figures are self-reported responses from KFF's Health Tracking Poll.

Data is reviewed about monthly, or sooner when a key source publishes a material update. Source links lead to the original publisher so readers can review definitions, methods, and full context.

Cite This Page

Apex Lab USA. "U.S. Obesity, Diabetes, and GLP-1 Statistics (2026)." Updated October 2, 2026. https://apexlabusa.com/weight-management-statistics.